Cargando…
Agonism of 4-1BB for immune therapy: a perspective on possibilities and complications
Costimulatory receptors on immune cells represent attractive targets for immunotherapy given that these molecules can increase the frequency of individual protective immune cell populations and their longevity, as well as enhance various effector functions. 4-1BB, a member of the TNF receptor superf...
Autores principales: | Salek-Ardakani, Shahram, Zajonc, Dirk M., Croft, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469789/ https://www.ncbi.nlm.nih.gov/pubmed/37662949 http://dx.doi.org/10.3389/fimmu.2023.1228486 |
Ejemplares similares
-
Targeting 4-1BB (CD137) to enhance CD8 T cell responses with poxviruses and viral antigens
por: Zhao, Yuan, et al.
Publicado: (2012) -
4-1BB agonism: adding the accelerator to cancer immunotherapy
por: Chester, Cariad, et al.
Publicado: (2016) -
4-1BB Agonism as a strategy to license immune checkpoint blockade in glioblastoma
por: Woroniecka, Karolina, et al.
Publicado: (2020) -
EZH2 Inhibition Compromises α4-1BB-Mediated Antitumor Efficacy by Reducing the Survival and Effector Programming of CD8(+) T Cells
por: Stairiker, Christopher J., et al.
Publicado: (2021) -
4-1BB Agonism Combined With PD-L1 Blockade Increases the Number of Tissue-Resident CD8+ T Cells and Facilitates Tumor Abrogation
por: Qu, Qiu-xia, et al.
Publicado: (2020)